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ABSTRACT 
 
Objectives 
Residential care facilities (RCFs) act as reservoirs for multidrug-resistant organisms (MDRO). 
There are scarce data on colonisation with MDROs in Africa. We aimed to determine the 
prevalence of MDROs and C. difficile and risk factors for carriage amongst residents of RCFs in 
Cape Town, South Africa. 
Methods 
We performed a cross-sectional surveillance study at three RCFs. Chromogenic agar was used 
to screen skin swabs for methicillin-resistant Staphylococcus aureus (MRSA) and stool samples 
for extended-spectrum beta-lactamase-producing Enterobacterales  (ESBL-E). Antigen testing and 
PCR was used to detect Clostridiodes difficile. Risk factors for colonisation were determined 
with logistic regression. 
Results 
One hundred fifty-four residents were enrolled, providing 119 stool samples and 152 sets of 
skin swabs. Twenty-seven (22.7%) stool samples were positive for ESBL-E, and 13 (8.6%) 
residents had at least one skin swab positive for MRSA. Two (1.6%) stool samples tested 
positive for C. difficile. Poor functional status (OR 1.3 (95% CI, 1.0 – 1.6)) and incontinence (OR 
2.9 (95% CI, 1.2 – 6.9)) were significant predictors for ESBL-E colonisation. There was a trend 
towards higher MRSA colonisation in frail care areas. 
Conclusion 
There was high prevalence of colonisation with MDROs but low C. difficile carriage, with 
implications for antibiotic prescribing and infection control practice.  
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CHAPTER 1: LITERATURE REVIEW 
 
Introduction 
Antibiotic resistance (ABR) is a global public health crisis which threatens to undermine our 
ability to treat bacterial infections [1, 2]. Therapeutic options to treat these infections are 
becoming limited as ABR has been evolving and disseminating at rates congruent with antibiotic 
usage [2]. ABR carries a high mortality and if no action is taken to limit its spread, it is estimated 
that up to 10 million annual ABR-related deaths will occur globally by 2050 [3]. 
ABR is common in South African referral hospitals. Local studies have shown that up to 74% of 
Klebsiella pneumoniae bloodstream isolates from South African (SA) public sector hospitals are 
extended-spectrum beta-lactamase (ESBL) producers [4], defined as being resistant to beta-
lactam antibiotics, including third-generation cephalosporins such as cefotaxime, ceftriaxone, 
and ceftazidime. Similarly, over half of Staphylococcus aureus bloodstream infections at Groote 
Schuur hospital (GSH) in Cape Town are resistant to cloxacillin [5]. Resistance of urinary 
Escherichia coli isolates to ciprofloxacin is increasing in SA with rates close to 20% [6].  
The rise in multiresistant bacteria has necessitated a change in empiric antibiotic prescribing 
practices, and patients with healthcare-associated infection (HAI) are now treated with broad-
spectrum second-line antibiotics such as carbapenems and vancomycin [7]. It has been shown 
that use of carbapenem antibiotics can lead directly to the emergence of carbapenem-
resistance during therapy, [8] and there are concerns that drug pressure from widespread 
carbapenem use may contribute to the emerging problem of carbapenem-resistant 
Enterobacterales  (CRE). CRE have been reported from all major public hospitals in SA. 
There are no published data on the prevalence of colonisation with ABR bacteria or 
Clostridiodes difficile amongst residents of residential care facilities (RCFs) in South Africa, but 
this is needed to guide recommendations for empiric antibiotic prescribing and infection 
control practices in these facilities.  
Mechanisms of antibiotic resistance 
Excessive antibiotic consumption in human health and the environment may contribute to the 
emerging problem of ABR [9, 10]. Empiric antibiotic prescribing practices (particularly with 
broad-spectrum antibiotics) lead to an increased risk of colonisation with ABR bacteria [11]. 
Bacteria have a remarkable ability to respond to an array of environmental threats that may 
threaten their existence. It may be underappreciated that some resistance mechanisms are 
ecologically ancient and that multiple mechanisms including 1) alterations of target site, 2) 
over-expression of efflux pumps and 3) protection of target sites may be used in isolation or in 
combination to confer resistance[9]. 
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ABR is linked to: 1) not utilising local antibiotic susceptibility data, 2) use of broad-spectrum 
antibiotics where not indicated, 3) treatment of contamination and colonisation rather than 
infection, 4) inappropriate surgical prophylaxis, and 5) prolonged treatment with antibiotics [7]. 
Higher levels of colonisation with ABR bacteria have been demonstrated in patients with a viral 
pneumonia who received prolonged antibiotic therapy after virus identification [11].  
Antibiotic resistance in Africa  
There is limited data on ABR in Africa and particularly Sub-Saharan Africa, with almost half of 
African countries reporting no ABR prevalence data. Certain factors have been highlighted by a 
systematic review about the flaws and inaccuracies of published data on ABR in Africa; these 
include 1) biased data from a limited number of countries with a strong regional 
preponderance, 2) questionable quality of susceptibility testing methods, 3) poor 
representation from rural populations and 4) lack of recent studies [12, 13].  
Despite this, a high prevalence of ABR to commonly used antibiotics has been demonstrated 
[12, 14]. A recent systematic review by Leopold et al. demonstrated high-level resistance to 
ampicillin (55.6-96%) and co-trimoxazole (51.0-86.7%) in patients with a febrile illness who had 
a positive Enterobacterales isolate (source of isolate unknown) [12]. The prevalence of 
resistance for respiratory isolates was variable with low rates reported for Streptococcus 
pneumoniae  to erythromycin (0.0-5.9%), while significant resistance to tetracycline was 
demonstrated for both Haemophilus influenzae (100%) and S.pneumoniae (42%)[12]. In a 
similar systematic review the median resistance of S.pneumoniae to penicillin was 25%, and 
34% for H.influenzae to amoxicillin. Resistance of Salmonella typhi to ciprofloxacin was 
reported to be rare [14].  
Communicable diseases in Africa are a major cause of death. They lead to extensive use of 
antibiotics with resultant ABR and its associated health and financial costs. No African country 
has a national surveillance system for ABR and few have national infection prevention and 
control (IPC) policies. Only two have implemented national action plans to combat ABR in 
accordance with a World Health Organisation (WHO) mandate [15]. 
Perhaps the greatest threat to human health is the emergence of multi-resistant Gram-negative 
bacteria and in particular ESBL producers and CRE; infections caused by these organisms are 
associated with increased mortality, longer hospital stays and excessive hospital costs [16, 17]. 
In a systematic review performed by Tadesse et al on ABR in Africa, high-level resistance of E. 
coli (20.0% and 19.5%) and K. pneumoniae isolates (34.2% and 46.7%) to 3rd generation 
cephalosporins (ceftriaxone and cefotaxime) was demonstrated. This is concerning as this may 
represent ESBL production [14].  
In 2011 the emergence of CRE was confirmed for the first time in South Africa. It was also the 
first time Klebsiella pneumoniae carbapenemase (KPC) producers had been demonstrated in 
Africa [16]. In 2013 the Center for Disease Control (CDC) in the United States declared CRE an 
immediate health threat requiring urgent and aggressive action. 
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The major factors for acquisition of CRE are similar to those for ESBL and include antibiotic 
exposure, intensive care unit admission, poor functional status, prolonged hospitalisation and 
surgery. Residential care facilities (RCFs) are known to be reservoirs of ESBLs but may also 
harbour CRE as they provide ideal conditions for their emergence and dissemination [1].  
Antibiotic resistance in South Africa 
 
 
The exact burden of ABR in South Africa (SA) is unknown. This is a major concern as infections 
result in the greatest burden of disease is SA. Empiric antibiotic prescribing practices which are 
not directed by local antibiogram data are frequently employed to combat these infections and 
may contribute to the development of ABR [18]. 
 
In most South African hospitals (public and private sector) antibiotic management is generally 
unacceptable and inappropriate in terms of 1) treatment duration, 2) avoidance of de-
escalation where possible and 3) use of multiple agents. Clinicians are unfamiliar with antibiotic 
stewardship principles and these recommendations are often ignored [1]. 
In a 2018 report by the National Institute for Communicable Diseases (NICD) on ABR in South 
African public sector hospitals (both HAI and community-acquired infections) the following 
alarming results were demonstrated. Among K. pneumoniae isolates: 36% were resistant to 
ciprofloxacin, 44% to piperacillin/tazobactam and 59% to gentamicin; with 65% (perhaps most 
alarmingly) being categorized as ESBL producers. Less than 30% of E.coli isolates demonstrated 
ESBL production. Approximately two-thirds of S. aureus isolates were categorised as methicillin-
resistant Staphylococcus aureus (MRSA). Low-level resistance of Enterococcus faecalis and 
Enterococcus faecium to glycopeptides was demonstrated [19].  
In a similar report on ABR surveillance from 4 South African private sector hospitals [20], 
antibiotic susceptibility testing was performed on ESKAPE (Enterococcus faecium, Enterococcus 
faecalis, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas 
aeruginosa, Enterobacter cloacae and Eschericia coli) bloodstream isolates. K.pneumoniae 
isolates demonstrated significant resistance to 3rd generation cephalosporins (55-57%) but 
were susceptible to carbapenems. A quarter of S.aureus bloodstream isolates were classified as 
MRSA. ESBL production in both K.pneumoniae and E.coli isolates was surprisingly lower in 
private compared to public sector hospitals. 
Healthcare-associated infections (HAI) carry a high mortality and result in excessive healthcare 
expenditure and prolonged hospital stay [21]. HAI are common in long-term care facilities [22]. 
Allegranzi et al. demonstrated that prevalence rates of HAI in developing countries (15.5 per 
100 patients) was considerably higher (3 times the level) than those reported from the US [23]. 
Infections that arise in residents from residential and long-term care facilities are now treated 
as healthcare-associated infections [7].  
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Residential care facilities 
The world’s population is aging and it is expected that the number of people aged greater than 
60 years will double by 2050; the majority of whom will reside in developing regions [24]. 
Residential care facilities (RCFs) are becoming major components of healthcare systems 
globally. In the US the number of residents in these facilities is expected to increase from 15 to 
27 million by 2050[25].  
Significant ambiguity exists in the literature regarding definitions of related terms 
such as “long term care facility”(a facility that provides room and board, as well as 
management of chronic medical conditions and 24-hour assistance with ADLs in 
patients who are physically and/or cognitively impaired) and “residential care 
facility” (a facility that provides room and board, housekeeping, supervision, 
assistance with ADLs and distributions of medications) and “nursing home” and  
their application in different countries. They are often used interchangeably. For 
example, in the United States, long term care usually occurs in residential care 
facilities, long-term care facilities (where nursing care is generally more intensive) 
and care homes. A recent international survey on the understanding of these terms 
demonstrated certain salient features that may be applied to characterize different 
facilities. These included 1) duration of stay (short versus long-term), 2) level of 
care required by residents with activities of daily living (ADL’s), 3) degree of skilled 
workers in these facilities (specialist nurses and physicians) and 4) goals in terms 
of improving resident functional status. Despite these suggestions many facilities 
have heterogenous populations requiring different levels of care who live in areas 
designated specifically for their needs, overlapping and confounding proposed 
definitions. It is important to describe details about number of residents, their 
functional status, availability of health staff, resources and services offered at a 
particular facility in addition to applying formal definitions[26].  
Populations in long-term care facilities (LTCFs), and residential care facilities (RCFs) in particular, 
are unique in that they (1) are institutionalised, (2) have multiple exposures to antibiotics, (3) 
have multiple medical comorbidities, (4) frequently have indwelling devices, (5) have frequent 
admissions to acute care facilities, (6) have impaired mobility, and (7) altered immunity. These 
factors place residents of RCFs at increased risk for colonisation and infection with ABR bacteria 
[27]. Colonisation (defined as asymptomatic carriage) with ABR bacteria is a well-established 
risk factor for infection with the same strain [17, 28], particularly in immunocompromised and 
elderly populations [29, 30]. RCFs are increasingly recognised as reservoirs for ABRs [17, 31, 32] 
and colonisation with ABR bacteria has been associated with outbreaks after referral of RCF 
residents to acute care facilities [33]. 
A point prevalence study of LTCFs in Italy found that three quarters of residents were colonised 
with ≥ 1 resistant organism, 64% with ESBL producers and 39% with methicillin-resistant S 
aureus MRSA [32]. Studies from the United States have shown similarly high rates of 
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colonisation with ESBLs, MRSA and ciprofloxacin-resistant Gram-negative bacilli [27]. Studies in 
high-income settings have demonstrated MRSA prevalence rates between 16% and 50% in 
various RCF populations [34, 35], [36] 
Additionally, residents of RCFs in high-income countries have high rates of Clostridioides difficile 
(previously Clostridium difficile) colonisation [37] and are susceptible to C. difficile infection 
(CDI) because of advanced age and frequent antibiotic use [38]. Colonisation with ABR 
organisms is also associated with prolonged hospital stay with increased hospital costs [39]. 
 
There is a large amount of variability in published ABR prevalence amongst long-term care 
facility residents. Estimates of extended-spectrum beta-lactamase-producing Enterobacterales 
(ESBL-E) colonisation in European series ranged between 4% and 64% [31, 32, 40, 41], similar to 
reports from the US [17, 27]. The wide range in prevalence is likely due to heterogeneity in 
study population. For example, inconsistent definitions of ‘long-term care facility’ are applied, 
some of which encompass acute care step down facilities expected to have higher prevalence 
of multi-drug resistant organsims compared with RCFs, where residents are less sick and have 
less exposure to antibiotics [42-44]. ESBL-E colonisation was detected in 12% of residents (n =  
119) in 3 residential aged care facilities in Australia[45]. In Belfast, Ireland, very high rates of 
ESBL-E colonisation (40%) were reported from 294 residents across 16 nursing homes [46]. 
 
Gram-negative bacteria have a propensity to acquire and develop antibiotic resistance [47]. 
These pathogens were previously considered to be nosocomial pathogens, but it is now evident 
that they have spread to other healthcare settings and the community. High levels of 
colonisation with these organisms have been demonstrated upon admission to acute care 
hospitals with the following: 1) advanced age (greater than 65 years), 2) resident of a RCF and 
3) recent antibiotic exposure identified as risk factors for colonisation [48]. Gram-negative 
bacteria are the most prevalent ABR pathogens recovered from RCF residents. For example, a 
cross-sectional study at a large LTCF in Boston found that 51% of sampled residents (n = 84) 
were colonised with multi-drug resistant Gram-negative bacteria compared to MRSA in 28% 
and vancomycin-resistant enterococci in 4% [17]. A longitudinal study conducted at a LTCF in 
Northern Ireland demonstrated similar results, with half of included residents (n = 64) positive 
for ESBL-E and a quarter for MRSA [40]. 
 
Antibiotic prescription in residential care facilities is frequently inappropriate in terms of 
indication and selection [49, 50]. This practice may negatively impact on patient outcomes by 
either providing insufficient antimicrobial cover or excessive risk of adverse effects such as C. 
difficile infection (CDI). CDI is endemic in LTCFs in developed countries and represents an 
important obstacle to care with incident rates of 2.3 cases/10,000 resident days reported [51]. 
There are limited data on the prevalence and impact of CDI amongst hospitalised patients in SA 
[52], and no data regarding C. difficile colonisation or CDI in LTCFs, but it may be an important 
problem due to widespread use of broad spectrum antibiotics and an increasingly ageing 
population. Studies at a Cape Town tertiary hospital found that 9 - 16% of acute diarrhoeal 
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illnesses were associated with C. difficile infection, and the annual incidence of hospital-acquired 
diarrhoea was much lower compared to high income countries [52, 53].  
Infection prevention and control (IPC) is a major issue in LTCFs and RCFs. From the 2014 ECDC 
surveillance report on ABR in Europe [54] only 42% of the 1181 surveyed facilities had an IPC 
committee. The majority (76%) had a protocol for the management of MRSA and ABR 
organisms. Isolation rooms were not commonly available in the majority of RCFs and as such 
effective barrier nursing could not be provided. No data on IPC and ABR in South African RCFs is 
available. 
 
Conclusion 
A significant knowledge gap exists on ABR in Africa. Major factors including poor hygiene, lack of 
infection prevention and control policies, access to quality health care, sanitation, public 
awareness and rampant antibiotic misuse all create the perfect environment for the emergence 
and dissemination of ABR bacteria. It is quite possible that we may be heading back to a pre-
antibiotic era where all our current available therapies will be rendered ineffective. 
Current South African guidelines recommend using carbapenems as empiric therapy for 
suspected healthcare-associated infections, including patients from RCFs. However, there are no 
published data on the prevalence of colonisation or infection with antibiotic resistant bacteria 
amongst residents of RCFs in SA. It is critical to understand the local antibiogram in RCFs in order 
to optimise empiric antibiotic selection and to reduce the unnecessary use of broad spectrum 
antibiotics. This has the potential of translating into improved patient outcomes and a reduction 
in the further emergence and spread of ABR. Determining the prevalence of colonisation with 
multidrug-resistant organisms and C difficile may also inform and potentially strengthen infection 
control practices in South African RCFs, and may help to guide local infection prevention and 
control (IPC) policy, which is currently not based on local data.  
 
 
 
 
 
 
 
 
 
15 
 
 
 
 
CHAPTER 2: PUBLICATION-READY MANUSCRIPT 
 
Colonisation with pathogenic drug-resistant bacteria and Clostridioides difficile among 
residents of residential care facilities in Cape Town, South Africa.  
 
 
Jason Septembera, Leon Geffenb, Kathryn Manninga, Preneshni Naickerc, Cheryl Faroa, Nolene de 
Jonga, Marc Mendelsona,d, Sean Wassermana,d,e 
 
Affiliations 
a. Department of Medicine, University of Cape Town, Cape Town, South Africa. 
b. Samson Institute for Ageing Research, Cape Town, South Africa. Institute of Ageing in Africa, 
University of Cape Town, Cape Town, South Africa. 
c. Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa. 
d. Division of Infectious Diseases and HIV Medicine, University of Cape Town, Cape Town, 
South Africa. 
e. Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape 
Town, South Africa. 
 
Author contributions 
JS contributed to the protocol, collected data, assisted with analysis, wrote the first draft of the 
manuscript; LG assisted with protocol development and edited the manuscript; KM assisted 
with data analysis; PN supervised the microbiological testing; CF and NdJ collected data; MM 
contributed to protocol development and edited the manuscript; SW conceived the study, 
developed the protocol, obtained funding, analysed data, edited the manuscript. 
 
 
 
Highlights 
 Extended spectrum beta-lactamase-producing bacteria detected in 22.7% (27/119)  
 Incontinence was an independent risk factor for colonisation  
 Methicillin-resistant Staphylococcus aureus found in 8.6% (13/152)  
 C. difficile colonisation was low 1.7% (2/119) 
 
 
16 
 
 
  
17 
 
ABSTRACT 
 
Objectives 
Residential care facilities (RCFs) act as reservoirs for multidrug-resistant organisms (MDRO). 
There are scarce data on colonisation with MDROs in Africa. We aimed to determine the 
prevalence of MDROs and C. difficile and risk factors for carriage amongst residents of RCFs in 
Cape Town, South Africa. 
 
Methods 
We performed a cross-sectional surveillance study at three RCFs. Chromogenic agar was used 
to screen skin swabs for methicillin-resistant Staphylococcus aureus (MRSA) and stool samples 
for extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E). Antigen testing 
and PCR was used to detect Clostridioides difficile. Risk factors for colonisation were 
determined with logistic regression. 
 
Results 
One hundred fifty-four residents were enrolled, providing 119 stool samples and 152 sets of 
skin swabs. Twenty-seven (22.7%) stool samples were positive for ESBL-E, and 13 (8.6%) 
residents had at least one skin swab positive for MRSA. Two (1.6%) stool samples tested 
positive for C. difficile. Poor functional status (OR 1.3 (95% CI, 1.0 – 1.6)) and incontinence (OR 
2.9 (95% CI, 1.2 – 6.9)) were significant predictors for ESBL-E colonisation. There was a trend 
towards higher MRSA colonisation in frail care areas. 
 
Conclusion 
There was high prevalence of colonisation with MDROs but low C. difficile carriage, with 
implications for antibiotic prescribing and infection control practice.  
 
Keywords: Residential care facility, antibiotic resistance, C. difficile, colonization, MRSA, ESBL, 
infection control, antibiotic stewardship 
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INTRODUCTION 
Antibiotic resistance (ABR) is a global public health crisis undermining the ability to treat 
bacterial infections. Excessive antibiotic consumption in human health and the environment 
may contribute to the emerging problem of ABR.  [55, 56]. The increase in multidrug-resistant 
organisms (MDRO) has necessitated a change in empiric antibiotic prescribing practices, and 
patients with healthcare-associated infections, including from residential care facilities (RCFs), 
are now often treated with second-line broad-spectrum antibiotics [57]. It is therefore critical 
to risk-stratify patients for infection with MDRO to support optimal antibiotic prescribing. 
 
Colonisation (defined as asymptomatic carriage) with MDROs is a well-established risk factor 
for infection with the same strain [17, 28], particularly in immunocompromised and elderly 
populations [29, 30]. RCFs are increasingly recognized as reservoirs for MDROs [17, 31, 32] and 
colonisation with MDR bacteria has been associated with outbreaks after referral of RCF 
residents to acute care facilities [33]. Additionally, residents of RCFs in high income countries 
have high rates of Clostridioides difficile (previously Clostridium difficile) colonisation [37] and 
are susceptible to C. difficile infection (CDI) because of advanced age and frequent antibiotic 
use [38].  
 
ABR is common in South African referral hospitals. Up to 70% of Klebsiella pneumoniae 
bloodstream isolates are extended-spectrum beta-lactamase (ESBL) producing strains [58], 
defined as being resistant to beta-lactam antibiotics, including third-generation cephalosporins 
such as cefotaxime, ceftriaxone, and ceftazidime. Almost a quarter of Staphylococcus aureus 
bloodstream infections at one tertiary academic centre were resistant to cloxacillin (methicillin-
resistant S. aureus, MRSA) [58]. There are no published data on the prevalence of colonisation 
with MDROs or C. difficile amongst residents of RCFs in South Africa, but this is needed to guide 
recommendations for empiric antibiotic prescribing and infection control practices in these 
facilities. We performed a cross-sectional microbiological prevalence survey at three RCFs in 
Cape Town, South Africa, to determine the prevalence of colonisation with ESBL-producing 
Enterobacterales (ESBL-E), MRSA and toxigenic C. difficile; and identify risk factors for 
colonisation. 
 
METHODS 
Study setting and population  
There are approximately 30 RCFs in the Cape Town metropolitan area. The majority of these 
institutions are operated by a non-profit organisation, the Cape Peninsula Organisation for the 
Aged (CPOA), which operate 25 facilities with ~3,000 residents. We selected three CPOA 
facilities for inclusion in a cross-sectional prevalence survey that were broadly representative of 
population demographics, functional status, and access to public and private acute-care 
hospitals.  
 
A random list of residents was generated at each facility, stratified by independent living and 
frail care areas. Frail care was defined as a specialised area in the RCF where residents require 
24-hour nursing care or supervision. These residents generally require assistance with activities 
of daily living (e.g. washing, dressing, eating), mobilisation, and taking of medicines [59]. 
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Residents identified from the random lists were approached for participation in the study. In 
addition to active recruitment, information leaflets were distributed and formal presentations 
were done at each facility to encourage participation. Residents (or their legal representative 
where appropriate) expressing interest in participating were asked to provide 
written/telephonic informed consent prior to enrolment.  
 
Sources of data 
Risk factors for colonisation with MDROs and C. difficile 
The following demographic and clinical data were collected at a single study visit through 
interviews and medical record reviews: presence of faecal/urinary incontinence, presence 
indwelling medical device, hospital exposure within last 6 months, systemic antibiotic exposure 
within the last 3 months, current use of proton pump inhibitors, functional and cognitive 
performance, presence of any skin ulceration, medical comorbidities (using the Charlston 
index), and any previous microbiological results in last 6 months. These were selected because 
of documented and putative associations with MDROs and C. difficile [17, 27, 29, 32, 40, 49]. 
Functional performance was assessed using the Katz Index of Independence in Activities of 
Daily Living (Katz ADL) which evaluates ability to perform ADLs and plan selfcare [60]. Scores ≤ 2 
indicate severe functional impairment, 3 - 5 mild-to-moderate impairment, and 6 indicates 
independence. The presence of dementia was ascertained from medical records and through 
clinical assessment by the study doctor combined with simple screening tools (3-word recall) 
and the assessment of the facility nursing staff [61, 62]. All data were collected using 
standardised case report forms. 
 
Microbiological data 
Skin swabs of nasal, axillary and inguinal areas were performed to screen for carriage of MRSA. 
Stool was collected from each participant to screen for colonisation with ESBL-E and toxigenic 
C. difficile. All specimens were processed at the National Health Laboratory Services (NHLS) 
clinical microbiology laboratory at Groote Schuur Hospital, Cape Town. Skin swabs and stool 
samples were plated onto chromogenic screening agar, ChromID MRSA and  ChromID ESBL agar 
plates (bioMérieux, Marcy I’Etoile, France). After incubation, suggestive colonies were 
identified and antibiotic susceptibility testing was performed using the Vitek 2 System 
(bioMérieux), and interpreted with Clinical Laboratory Standards Institute (CLSI) 2017 criteria. 
We did not screen for vancomycin-resistant Enterococci due to low prevalence in South African 
hospitals. Although carbapenem-resistant Enterobacteriaceae were not specifically screened 
for, these are also detected on the ChromID ESBL agar plates. An automated nucleic acid 
amplification test, Xpert C. difficile (Cepheid, Sunnyvale, CA, USA) was initially used to screen 
for toxigenic C. difficile in stool samples. This was later changed to a two-step algorithm where 
samples were screened with the dual antigen (glutamate dehydrogenase (GDH) and toxins A 
and B) with a C. Diff Quik Chek Complete test (TechLab, Blacksburg, VA, USA). C. difficile 
carriage was defined by positivity of both GDH and toxin assays; GDH-positive and toxin-
negative samples reflexed to Xpert C. difficile testing.  
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Analysis 
The primary outcome measure was the proportion of residents colonised with MDROs and 
toxigenic C. difficile. Assuming a combined population of ~420 residents at the recruitment 
facilities, a sample size of 150 was planned detect an ESBL-E colonisation prevalence of 20% 
with 5% precision. Associations between MDRO colonisation and participant characteristics 
were identified using the Wilcoxon rank sum test for continuous variables and 2 test for 
categorical variables. Logistic regression was used to determine the risk factors associated with 
colonisation. Univariable analysis included the following pre-specified variables, plus significant 
associations identified in the descriptive analysis: hospitalisation and/or antibiotic exposure 
within the previous 3 or 6 months, non-ambulatory status, presence of pressure ulcers, and 
Charlson score. These variables were included in a multivariable model to adjust for potential 
confounding, using a backward stepwise selection strategy (P < 0.2). We combined significant 
predictors into risk scores by assigning a point to each variable per 1-fold increased odds of 
colonisation. The predictive accuracy of the score was evaluated by calculating the area under 
the receiver operating characteristic curve (AUROC). Analysis was performed in Stata (Version 
14.2; Stata Corp, College Station, Texas, USA). 
 
Ethics 
The study was approved by the University of Cape Town Human Research Ethics Committee 
(reference number 806/2016). 
 
RESULTS 
Characteristics of study population 
One hundred fifty-four participants were enrolled from three RCFs between March 2017 and 
April 2018; the cohort included 59 residents from frail care and 95 from independent living 
areas. Median age was 79 years (interquartile range (IQR) 74 – 86) and 111 (72%) residents 
were female. Thirty-seven (24%) participants were bed- or chair-bound and the majority (n = 
102, 67%) had Katz scores ≥ 5, indicating limited/no functional impairment. Forty-five (29.2%) 
had a diagnosis of dementia; median Charlson score was 1 (IQR 0 – 2). Urinary incontinence was 
present in 56 (36%) of participants and faecal incontinence in 24 (16%). Median time in the 
residence at the time of study participation was 41 months (IQR 17 – 72). Eighteen (12%) 
participants had been admitted to hospital in the previous six months and 38 (25%) had 
received systemic antibiotics in the previous three months. 
 
Prevalence of colonisation with MDROs and C. difficile 
Stool samples were obtained from 119 residents. ESBL-E colonisation was detected in 27/119 
(23%), comprising the following organisms: E. coli (17/27 isolates, 63%), K. pneumoniae (5/27 
isolates, 19%), E. cloacae (4/27 isolates, 15%), and a single participant with mixed growth of E. 
cloacae and E. coli. Additional resistance to ciprofloxacin was detected in 19% (5/27), 
piperacillin-tazobactam in 11% (3/27) and gentamicin in 30% (8/27) (Figure 1). All isolates were 
susceptible to carbapenems. 
 
One hundred fifty-two sets of skin swabs were collected. A set was defined as three single 
swabs used to sample the nares, axillae and groin from an individual participant. MRSA was 
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recovered from 13/152 (9%) individuals. The frequency of MRSA colonisation according to 
sampling site was: nasal 47%, groin 33% and axillae 20%. Four (3%, n = 117) participants had 
evidence of concurrent MRSA and ESBL-E colonisation. 
 
Two (1.7%, n = 119) stool samples from asymptomatic residents were positive for C. difficile; 
both detected using the GDH antigen and toxin assay (n = 81). The remainder (n = 38) were 
tested using a nucleic acid amplification test with no positive results.  
 
 
Factors associated with MDRO colonisation  
A significantly higher proportion of participants colonised with ESBL-E had urinary and/or faecal 
incontinence (59.3% vs. 33.7% in those not colonised; P = 0.02) (Table 1). The prevalence of 
ESBL-E amongst participants with incontinence was 34% (16 cases, n  = 47), translating into a 
2.9-fold increased odds (95% CI 1.2 – 6.9) of EBSL-E colonisation with any form of incontinence. 
ESBL-E colonisation was also associated with lower Katz ADL scores; there was a 1.3-fold (95% 
CI 1.0 - 1.6; P = 0.03) increased odds of colonisation for every 1-point reduction in the Katz ADL. 
Incontinence remained an independent predictor of ESBL-E colonisation on multivariable 
analysis, adjusted odds ratio (OR) 3.2 (1.3 – 8.1) (Table 2). Half of participants with a poor 
functional status (Katz score ≤ 2) and incontinence were colonised with ESBL-E (53.3%; 8 cases, 
n=15), significantly higher and in contrast to those without either of these factors: ESBL-E 
colonisation 13.8% (9 cases, n=65).  
 
However, the discriminatory value of this risk factor combination was poor with area under the 
curve of the receiver operating characteristics curve (AUROC) 0.67 (95% CI 55 – 78). There was 
a trend towards having a higher median Charlson co-morbidity score in colonised individuals (2 
vs. 1 in non-colonised), although this was not statistically significant (P = 0.06). There were no 
other associations between pre-specified risk factors and colonisation with ESBL-E (Table 1).  
 
As shown in Table 3, participants colonised with MRSA had resided in their respective facilities 
for significantly less time compared to those who were not colonised with MRSA (20.9 vs 44.2 
months; P = 0.04). There was a numerically higher proportion of MRSA-colonised individuals in 
frail care areas (61.5% vs. 36.0% in independent living areas; P = 0.07). The prevalence of MRSA 
colonisation amongst those in frail care was 13.8% (8 cases, n = 58), a non-significant 2.8-fold 
(95% CI, 0.9 – 9.2) increased odds of MRSA compared with participants residing in independent 
living areas. Multivariable analysis was not performed for MRSA colonisation because of low 
case numbers. 
 
DISCUSSION  
Determining the prevalence of colonisation with MDROs and C. difficile amongst RCF residents 
is important to inform empiric antibiotic selection and infection control practices. In South 
Africa, guidelines for managing RCF residents with infection are not based on local data, and 
this knowledge gap formed the rationale for the present study. We found that amongst 154 
residents at three RCFs in Cape Town, the prevalence of ESBL-E and MRSA colonisation was 23% 
and 8%, respectively. C. difficile carriage was uncommon, identified in only two participants. 
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Urinary or faecal incontinence and poor functional status were associated with ESBL-E carriage, 
and there was a trend towards increased risk of MRSA colonisation amongst residents in frail 
care.  
 
There is a large amount of variability in published MDRO prevalence amongst long-term care 
facility residents. Estimates of ESBL-E colonisation in European series ranged between 4% and 
64% [31, 32, 40, 41], similar to reports from the US [17, 27]. The wide range in prevalence is 
likely due to heterogeneity in study population. For example, inconsistent definitions of ‘long-
term care facility’ are applied, some of which encompass acute care step down facilities 
expected to have higher prevalence of MDROs compared with RCFs, where residents are less 
sick and have less exposure to antibiotics [42-44]. ESBL-E colonisation was detected in 12% of 
residents (n = 119) in 3 residential aged care facilities in Australia [63]. Similar to our study the 
majority of residents were highly mobile and no association between recent antibiotic use, 
length of stay, urinary catheterisation, presence of diarrhoea and ESBL-E colonisation was 
found. The reported rates of C. difficile were also very low (1%), as in our study. In Belfast, 
Ireland, very high rates of ESBL-E colonisation (40%) were reported from 294 residents across 
16 nursing homes; in contrast to our study, residents generally had high exposure to systemic 
antibiotic therapy, which was a significant risk factor for colonisation with ESBL-E [46]. 
 
These observations support our hypothesis that, based on the epidemiology of MDROs in acute 
care facilities in South Africa, the local prevalence of colonisation in RCFs would be similar to 
that in high income settings. This high prevalence of ESBL-E colonisation (23%), plus additional 
resistance to ciprofloxacin (18%) amongst residents from RCFs in Cape Town suggests risk of 
treatment failure with the use of third generation cephalosporins and quinolones for common 
infection syndromes such as urinary tract infection and possibly pneumonia (as most 
pneumonia is frequently caused by Gram-positive bacteria). 
.  
Our findings are consistent with others showing Gram-negative bacteria to be the most 
prevalent multi-resistant pathogens recovered from RCF residents. For example, a cross-
sectional study at a large LTCF in Boston found that 51% of sampled residents (n = 84) were 
colonised with multi-drug resistant Gram-negative bacteria compared to MRSA in 28% and 
vancomycin-resistant enterococci in 4% [17]. A longitudinal study conducted at a LTCF in 
Northern Ireland demonstrated similar results, with half of included residents (n = 64) positive 
for ESBL-E and a quarter for MRSA [40]. 
 
Poor functional status (i.e. residents requiring assistance with ADLs) and impaired mobility, with 
or without dementia, have been identified as significant factors for ESBL-E and MRSA 
colonisation [32]. In our study poor functional status (i.e those with a low Katz ADL score) and 
any form of incontinence were significantly associated with ESBL-E colonisation. The prevalence 
of ESBL-E colonisation with the combination of incontinence and Katz score ≤ 2 was high (53%), 
but had poor discriminatory value. Similar observations have been reported from high-income 
countries. In a study from Melbourne, Australia, where 115 residents from 4 facilities were 
screened, faecal incontinence and significant functional dependence (low Katz ADL score) were 
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also shown to be major factors for colonisation with MDROs [64]. Similar predictors for MDR 
Gram-negative colonisation were found in a LTCF cohort in Boston: faecal incontinence, need 
for assistance with ADLs, advanced dementia and residing in units where more intensive 
nursing care was provided [17]. These factors may lead to higher levels of staff contact which 
result in cross-transmission [65]. It has been suggested that intensified infection prevention and 
control (IPC) measures, such as wearing of gowns and gloves by healthcare workers [66] and 
enhanced hygiene practices should be implemented for residents at high risk for MDRO 
colonisation [67]. Screening for ESBL-E and isolation of carriers outside of outbreak settings is 
controversial, and more evidence is required to understand the impact of this strategy to 
prevent transmission [68]. 
 
A comparatively low prevalence of MRSA colonisation (9%) was seen in our cohort, in contrast 
to studies in high income settings where MRSA prevalence ranged between 16% and 50% in 
various LTCF populations [34, 35], [36]. This discrepancy may be a consequence of circulating 
epidemic MRSA strains in the United States [69], which has not been the case in South Africa 
[70]. Shorter median time spent in RCFs was associated with MRSA colonisation in our study 
(20.9 versus 44.2 months for those not colonised). This may have been a chance finding due to 
low case numbers, and is susceptible to confounding factors which could not be adjusted for, 
such as visits to acute care facilities, which increases risk of MRSA acquisition [27], and 
differences in antibiotic therapy and IPC practices of attending physicians. There was a trend 
towards higher MRSA colonisation amongst residents in frail care; this has been observed in 
other settings and is possibly related to more frequent use of invasive medical devices, chronic 
wounds, and antibiotic exposure in this population [71]. 
 
CDI is endemic in RCFs in high income countries with incidence rates of 2.3 cases/10,000 
resident days reported [51]. In contrast, only 2/119 (< 2%) samples were positive for C. difficile 
in our study. Studies at a Cape Town tertiary hospital found that 9 - 16% of acute diarrhoeal 
illnesses were associated with C. difficile infection, and the annual incidence of hospital-
acquired diarrhoea was much lower compared to high income countries [72, 73]. These 
observations reflect the wide prevalence ranges for C. difficile which has a complex 
epidemiology across different settings, influenced by strain type, infection control and 
prescribing practices [45, 74, 75]. Active surveillance for carriers of toxigenic C. difficile has been 
advocated in high burden settings [76], but our findings suggest this may not be necessary in 
South African RCFs.  
 
Our study has several limitations. As a result of limited resources we could not recruit residents 
from all RCFs in Cape Town, and selected a subset on the basis of representative demographics. 
Further limiting generalisability, we were unable to include all residents from the three 
participating facilities, and there were imbalances in number of participants across the RCFs. 
Although we generated randomised lists of residents at each facility, there is inherent bias in 
the recruitment process, and residents with MDRO colonisation may have been systematically 
excluded.  We attempted to preferentially enrol residents in frail care areas in order to capture 
the highest risk group, but consent was more challenging in this population, skewing the 
sample towards independent living and less functional impairment. Our power to detect 
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associations with MDRO colonisation was limited by low prevalence of MRSA colonisation, and 
because only 77% (119/154) of participants were willing to provide stool samples for ESBL-E 
screening. Although reliable systems were in place to collect clinical data, antibiotic exposure 
may have been underestimated as medications received during hospital admissions and 
clinic/general practitioner visits were incompletely documented. Finally, data collection 
occurred over a prolonged period due to logistic limitations and this may have influenced our 
results as colonisation prevalence is known to change over time [77].  
 
Notwithstanding these limitations, our survey demonstrated a high prevalence of colonisation 
with MDROs but low C. difficile carriage amongst residents of RCFs in Cape Town, South Africa. 
This has important implications for practice, including review of local antibiotic prescribing 
guidelines to ensure appropriate initial therapy for RCF residents. Crucially, IPC interventions 
such as improved healthcare worker hand hygiene and barrier nursing, as well as antibiotic 
stewardship, should be implemented, and possibly targeted at higher risk residents, including 
those with incontinence and lower functional status, to interrupt the transmission of MDROs in 
RCFs.  
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TABLES AND FIGURES 
 
Table 1. Associations with extended-spectrum beta-lactamase-producing Enterobacterales 
(ESBL-E) colonisation 
 Colonised  
(n = 27) 
Not colonised 
(n = 92) 
Prevalence 
ESBL-E (%) 
P-value 
Facility 
Facility 1 
Facility 2 
Facility 3 
 
15 (55.6) 
12 (44.4) 
0 (0) 
 
33 (35.9) 
53 (57.6) 
6 (6.5) 
 
31.2 
18.5 
0 
 
0.109 
Time in facility, months 43.9 (22.9 – 
65.2) 
40.7 (14.3 – 
73.6) 
NA 0.992 
Frail care resident 12 (44.4) 26 (28.3) 31.6 0.113 
Any incontinence 16 (59.3) 31 (33.7) 34.0 0.017 
Hospital exposure in last 6 
months 
10 (37.0) 21 (22.8) 32.3 0.139 
Systemic antibiotic exposure last 
3 months 
8 (29.6) 18 (20.0) 30.8 0.291 
Previous positive culture from a 
clinical specimena 
7 (36.8)b 20 (39.2)c 25.9 0.856 
Bedbound or chair-bound 9 (33.3) 17 (18.5) 34.6 0.100 
Katz score: median (ranges)  6 (2-6) 6 (4-6) NA 0.048 
Dementia 10 (37.0) 20 (21.7) 33.3 0.107 
Charlson index score 2, (1-2) 1, (1-2) NA 0.058 
Currently using PPI 8 (29.6) 19 (20.6) 19.6 0.090 
Data are median or n (percent). PPI, proton pump inhibitor 
a. Includes microbiological evidence of S. aureus, Enterobacterales, C. difficile 
b. n = 19 
c. n = 51 
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Table 2. Univariable and multivariable analysis of risk factors associated with extended-
spectrum beta-lactamase-producing Enterobacterales (ESBL-E) colonisation.  
 
 Univariable Multivariable (n = 117) 
Parameter Odds ratio (95% CI) P value 
Odds ratio (95% 
CI) 
P value 
Any incontinence 2.9 (1.2 – 6.9) 0.019 3.2 (1.3 – 8.1) 0.013 
Katz ADL 1.3 (1.0 – 1.6) 0.027  
Systemic antibiotic 
exposure last 3 
months 
1.7 (0.6 – 4.5) 0.294  
Hospital exposure in 
last 6 months 
1.9 (0.8 – 4.9) 0.143 2.0 (0.8 – 5.5)   0. 154 
Non-ambulatory 2.2 (0.8 – 5.7) 0.105  
Charlson score 1.4 (0.9 – 2.2) 0.119  
Katz ADL (Activity of Daily Living) score, antibiotic exposure, non-ambulatory status, and 
Charlson score were removed from the multivariable model due to P-value exceeding including 
pre-defined inclusion threshold (P < 0.2). Presence of pressure ulcers was not included as a 
predictor due to insufficient data (n = 4). 
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Table 3. Associations with methicillin resistant Staphylococcus aureus (MRSA) colonisation 
 
 Colonised  
(n = 13) 
Not colonised 
(n = 139) 
Prevalence 
of MRSA 
(%) 
P-value 
Facility 
Facility 1 
Facility 2 
Facility 3 
 
6 (46.2) 
5 (38.5) 
2 (15.4) 
 
55 (39.6) 
78 (56.1) 
6 (4.3) 
 
9.8 
6.0 
25.0 
 
0.167 
Time in facility, months 20.9 (17.3 - 
36.4) 
44.2 (17.6 - 
76.7) 
NA 0.042   
Frail care resident 8 (61.5) 50 (36.0) 13.0 0.070 
Any incontinence 5 (38.5) 57 (41.0) 8.1 0.858 
Hospital exposure in last 6 
months 
2 (15.4) 39 (28.1) 4.9 0.325 
Systemic antibiotic exposure last 
3 months 
3 (25.0) 35 (25.6) 7.9 0.967 
Previous positive culture from a 
clinical specimena 
4 (50)b 33 (40.2)c 10.8 0.592 
Mobility status (bedbound/chair 
bound) 
5 (38.5) 32 (23.0) 13.5 0.215 
Katz score: median (ranges) 5.5 (4-6) 6 (3-6) NA 0.766 
Dementia 4 (30.8) 41 (29.5) 8.9 0.923 
Charlson index score 1 (0-2) 1 (0-2) NA 0.848 
Currently using PPI 3 (23.1) 10 (7.2) 8.1 0.701 
Data are median (IQR) or n (percent). PPI, proton pump inhibitor 
a. Includes microbiological evidence of S. aureus, Enterobacteriaceae, C. difficile 
b. n = 8 
c. n = 82 
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Figure 1. Susceptibility of extended-spectrum beta-lactamase-producing Enterobacterales 
(ESBL-E)  isolates to commonly-used antibiotics 
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VOORKOMS VAN EN RISIKOFAKTORE VIR KOLONISASIE MET PATOGENIESE  
MEDISYNEBESTANDIGE  BAKTERIEË EN CLOSTRIDIUM DIFFICILE (C.DIFFICILE ) ONDER INWONERS VAN 
LANG - EN MEDIUM TERMYN SORG FASILITEITE IN KAAPSTAD ( PREDiCT)   
  
DEELNEMER TOESTEMMING  
  
DEUR DIE VOLGENDE TE ONDERTEKEN, STEM EK SAAM DAT:   
1. Ek die informasie pamflet, wat geskryf is in ‘n taal wat ek  vlot kan praat en gemaklik mee is, 
deeglik deurgelees het en dat die pamflet toepaslik vertaal  is.   
2. Ek die kans gekry het om vrae te vra, wat ook beantwoord was.    
3. Ek verstaan dat deelname aan hierdie studie uit vrye keuse is.     
4. Ek toestemming gee vir die gebruik en verspreiding van my mediese data en private informasie, 
soos verduidelik in die informasie pamflet.   
5. Ek ten enige oomlik kan besluit om te onttrek vanuit deelname aan die studie of kan kies om nie 
deel te neem nie, deur die studente dokter of die verpleegster in kennis te stel.   
6. As ek die studie vir enige rede verlaat, kan die navorsingspan steeds my inligting gebruik wat 
verskaf was tot op daardie punt.   
 
__________________        ___________________________                 _______ 
Naam van deelnemer                    Handtekening / Vingerafdruk                          Datum       
  
  
____________________               ____________________________                 _______                   Naam van 
persoon wat                   Handtekening / Vingerafdruk                           Datum         toestemming neem         
 
 
  
6. Participant consent form (Afrikaans) 
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VOORKOMS VAN EN RISIKO FAKTORE VIR KOLONISASIE MET PATOGENIESE MEDISYNEBESTANDIGE  
BAKTERIEË EN CLOSTRIDIUM DIFFICILE (C.DIFFICILE )  ONDER INWONERS VAN LANG - EN MEDIUM 
TERMYN SORG FASILITEITE IN KAAPSTAD ( PREDiCT) 
   
Toestemmingsvorm vir naasbestaande of wettig volmagtigde persoon van die inwoner wat nie 
toestemming kan gee nie 
  
Ek ……………………………………………………………………..……. (hiermee bekend as die wettig volmagtigde 
persoon) het volmag vir  ………………………………………………………………..……………  
(hiermee bekend as die inwoner).   
  
Ek  is verband aan die inwoner op die volgende wyse:   
……………………………………………………………………………………………………. en is as gevolg van  
hierdie verhouding in staat om namens die inwoner toestemming te gee, wat self nie toestemming kan 
gee nie vir die volgende rede:   
…………………………………………………………………………………………………………………………………  
As die wettig aangestelde volmagtige of naasbestaande, is ek bereid om  
………………………………………………………………………..  te help met die besluitneming  om deel te neem aan die 
studie.   
  
Bevestiging van die verhouding met inwoner of wettige bewyse van volmagtigde status.   
1. Identiteitsdokument  
2. Bestuurderslisensie  
3. Paspoort   
4. Dokumentasie van kurator persona of kurator bonis  
   
 
 
 
7. Proxy consent form (Afrikaans) 
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*’n Aanvaarbare naasbestaande sluit in: gade of vennoot, volwasse kind; volwasse broer of suster.  In die 
geval van verbale toestemming, sal ‘n onpartydige getuienis bevestig dat die bogenoemde volmagtigde 
gekontak was en verskaf was met bogenoemde inligting.    
  
  
     
NAAM VAN ONPARTYDIGE GETUIENIS              HANDTEKENING                                 DATUM   
  
  
DEUR DIE VOLGENDE TE ONDERTEKEN, STEM EK SAAM DAT:   
 
1. Ek die informasie pamflet, wat geskryf is in ‘n taal wat ek  vlot kan praat en gemaklik mee is, 
deeglik deurgelees het en dat die pamflet toepaslik vertaal  is.   
2. Ek die kans gekry het om vrae te vra, wat ook beantwoord was.    
3. Ek verstaan dat deelname aan hierdie studie uit vrye keuse is en van my af hang.       
4. Ek toestemming gee vir die gebruik en verspreiding van die inwoner / pasiënt se mediese data 
en private informasie, soos beskryf in die informasie pamflet.   
5. Ek enige oomlik kan  besluit,  ter wille van die  inwoner of pasiënt , om nie deel te neem nie, of 
te onttrek uit die studie deur die studente dokter of verpleegster, op enige oomblik, in kennis te 
stel.   
6. Indien die inwoner / pasiënt die studie verlaat vir een of ander rede, die navorsingspan steeds 
van die inligting kan gebruik, wat tot op daardie punt verskaf was.   
  
  
Inwoner / pasiënt naam …………………………………………………………………………………………………………  
  
____________________________                      _________________                       ___________ 
Naam van volmagtigde persoon                              Handtekening                                 Datum   
  
Vehouding tot die pasiënt …………………………………………………………………………………… (drukskrif asseblief).   
 
Naam van persoon wat die toestemming neem           Handtekening                         Datum   
  
Ek het die doel en natuur van die studie ten volle aan die deelnemer verduidelik.  In die geval van 
verbale toestemming, sal ‘n onpartydige getuienis bevestig dat ingeligte toestemming van die 
bogenoemde persoon verkry was. Die volmagtigde persoon was ingelig oor die gevare en voordele van 
die navorsingsprojek en het dit verstaan en is nogtans bereid om toestemming te gee vir deelname, uit 
vrye keuse en sonder onbehoorlike beïnvloeding of onvanpaste aansporing.  
  
                     
Naam van onpartydige getuienis                              Handtekening                                Datum  
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PREDiCT CRF V1.0 Feb 2017 
 
 
Date …………/…………/…………   
Study ID 
Facility Name (1=HH, 2=Booth, 3=CPOA) 
 
Demographics 
1. Initials…………………………………………………………………………………… 
2. Date of birth …………………………………………………..………    …………/…………/………… 
2. Gender (1=male, 2=female)...…………………………............................................   
3. Race………….…………………………………………………………………………………….… 
      (1=Coloured, 2=Black, 3=White, 4=Asian, 5=other: specify_______________) 
 
Facility details 
4.1 Date admitted/moved to facility ……………………………   …………/…………/………… 
4.2 Which section of the facility do you live in ……………………………………..    
      (1=general living area, 2=frail care area, 9=N/A (not in RCF)) 
 
CLINICAL DETAILS 
Continence 
5.1 Faecal incontinence……………………………………………………………….……….. 
8. Case report form 
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5.2 Urinary incontinence……………………………………………………….……………... 
 
Indwelling medical devices 
6.1 Urinary catheter……………………………………………………….………………..…... 
6.2 NG tube…………………………………………………………….……………………….…… 
6.3 PEG………………………………………………………………………………………………… 
6.4 IV line……………………………………………………………………………………………… 
6.5 Intermittent catheterisation…………………………………………………………… 
6.6 Other (specify)…………………………………………………………………………………  
 
Hospital exposure in the previous 6 months 
7.1 Emergency department visit (<24 hours)……….………………………….…….  
7.2 Admitted to ward……………………………………………………….…………………… 
7.3 Date of most recent exposure………………………………..   …………/…………/………… 
7.4 Name of healthcare facility attended…………………….____________________ 
 
Antibiotic exposure 
8.1 Systemic antibiotic use in the last 3 months……………………………………. 
8.2 Indication………………………………………………………………………………………..  
(1=UTI, 2=LRTI, 3=URTI, 4=SSTI,5=diarrhoea, 6=other________________________) 
8.3 Duration of treatment (in days)……………………………………………………….   
8.4 Class of antibiotic #1………………………………………………………………………. 
8.5 Class of antibiotic #2………………………………………………………………………. 
(1=BL, 2=BL/BLI, 3=cephalosporin, 4=quinolone, 5=macrolide, 6=carbapenem, 7=other:______________) 
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Microbiology within previous 6 months 
9.1 Specimen ……………………………………………………………………………………….. 
 (1=blood, 2=urine, 3=skin/wound, 4=other: specify_______________________________) 
9.2 Organism ………………………………………………………………………………………..  
 (1=enterobacteriaceae,2=C.difficile,3=Staphylococcus aureus, 4=other:________________________) 
9.3 Susceptibility ………………………………………………………………………………….. 
   (1=WT, 2=ceftriaxone-resistant, 3=quinolone-resistant, 4=ceftriaxone plus quinolone-resistant, 5=MRSA) 
9.4 Previous C.difficile diarrhoea………………………………………………………….. 
9.5 If yes, please include date……………………..………………    …………/…………/………… 
Functional Status 
10.1 Mobility status…………………………………………………………………………….. 
           (1=bedbound, 2=chair-bound, 3=walks with assistance, 4=walks independently) 
10.2 Katz Index of IADL score ……………………………………………………………….  
10.4 Three-word recall score……………………………………………………………….. 
10.3 Clinical diagnosis of dementia………………………………………………………. 
 
Concomitant medication 
11.1 Currently using systemic corticosteroids…………………………………..…… 
11.2 Currently using proton pump inhibitor……………………….…………………. 
 
Co-morbidities 
12.1 Diabetes Mellitus                                                  12.2 Hypertension……   
12.3 COPD……………….                                                    12.4 Malignancy………      
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12.5 HIV………………….                                                     12.6 Tuberculosis……..    
12.7 Heart failure……..                                                   12.8 Other………………..                 
                                                                                           (specify________________) 
12.9   Modified Charlson co-morbidity index score………………................... 
12.10 Current pressure sore or skin ulceration………………………………….….. 
 
Sample collection 
14.1 Stool/rectal sample collected ………………………………………………………. 
14.2 Date……………………………………………………………………..   …………/…………/………… 
14.3 Skin swabs collected………………………………………………………………………. 
14.4 Date ………………..…………………………………………………..   …………/…………/………… 
Data entered by_________     Data captured by___________  
Date …………/…………/…………   Date  …………/…………/………… 
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9. The International Journal of Infectious Diseases (IJID) instructions to authors 
 
Instructions to authors: The International Journal of Infectious Diseases(IJID) is published monthly by 
the International Society for Infectious Diseases. 
 
IJID is a peer-reviewed, open access journal and publishes position papers, original clinical and laboratory-based 
research, together with reports of clinical trials, reviews, exceptional case reports. The interest areas of the IJID are 
epidemiology, clinical diagnosis, treatment, and control of infectious diseases with particular emphasis placed on 
under-resourced countries. The IJID does not publish veterinary studies and studies based on animal models alone. 
Manuscript types 
 
Original articles on infectious disease topics of broad interest. We particularly welcome papers that discuss 
epidemiological aspects of international health, clinical reports, clinical trials and reports of laboratory investigations. 
Original articles should not exceed 3500 words in length.The word count is from the introduction through to the end of 
the conclusion/discussion and does not include abstract, tables, figures, acknowledgements or reference list. 
 
Reviews on topics of importance to readers in diverse geographic areas. These should be comprehensive and fully 
referenced.  
 
Article requirements: Word count for the main part of the manuscript from introduction to conclusion/discussion: 2,500 
to max of 4000 words. One or two figures/tables, a brief abstract, an introduction, a conclusion, and no more than 30 
references. 
 
Perspectives are papers that advance a hypothesis or represent an opinion relating to a topic of current interest or 
importance. They should be fully referenced, and should not exceed 2000 words in length. 
 
Correspondence relating to papers recently published in the Journal, or containing brief reports of unusual or 
preliminary findings. Maximum length 400 words, one table or figure and a maximum of 10 references. 
 
Case Reports must be carefully documented and must be of importance because they illustrate or describe unusual 
features or have important therapeutic implications. Maximum length 1200 words and a maximum of 1 table or figure. 
Case reports require an abstract, but this does not need to be a structured abstract and should include no more than 
15 references. 
 
Short Communications brief reports of unusual or preliminary findings. Maximum length 800 words, two tables or 
figures and a maximum of 10 references. 
 
Medical Imagery: We would like to invite submission of high-quality, interesting and instructive images (such as 
clinical and other photographs, figures or diagrams, photomicrographs, or diagnostic imaging) suitable for the general 
readership of IJID. These should include no more than 200 words of explanatory text, and under 5 references. It is 
necessary to have appropriate permissions from subjects for an identifiable clinical image to be published. 
Essential title page information 
 
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and 
formulae where possible. 
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and 
check that all names are accurately spelled. You can add your name between parentheses in your own script behind 
the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the 
names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of 
the appropriate address. Provide the full postal address of each affiliation, including the country name and, if 
available, the e-mail address of each author. 
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, 
also post-publication. This responsibility includes answering any future queries about Methodology and 
Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the 
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corresponding author. 
• Present/permanent address. If an author has moved since the work described in the article was done, or was 
visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's 
name. The address at which the author actually did the work must be retained as the main, affiliation address. 
Superscript Arabic numerals are used for such footnotes. 
 
Covering letter 
 
Manuscripts must be accompanied by a covering letter stating that the current "Instructions to Authors" have been 
read by all authors, thereby indicating compliance with those instructions and acceptance of the conditions posed. 
The letter should state that the authors have seen and agreed to the submitted version of the paper, that all who have 
been acknowledged as contributors or as providers of personal communications have agreed to their inclusion, that 
the material is original and that it has been neither published elsewhere nor submitted for publication simultaneously. 
In addition the letter should state that if accepted, the paper will not be published elsewhere in the same form, in 
English or in any other language, without written consent of the copyright holder.Please also note that Authors should 
provide a list of 3 potential reviewers (e-mail and affiliation) who are knowledgeable in the subject matter, have no 
conflict of interest, and are likely to agree to review the manuscript. Please ensure that 2 of the potential reviewers 
are from a different country to the authors. 
 
Highlights 
 
Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core 
findings of the article and should be submitted in a separate editable file in the online submission system. Please use 
'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet 
point). You can view example Highlights on our information site. 
 
Abstract 
 
A structured abstract of 150 to 200 words must be provided as part of each manuscript, except correspondence. The 
abstract should consist of four paragraphs, with the following headings: objectives, design or methods, results, 
conclusions, or alternative headings appropriate to the format of the paper. The abstract should not refer to footnotes 
or references. 
 
Graphical abstract 
 
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The 
graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the 
attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission 
system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. 
The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: 
TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site. 
Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in 
accordance with all technical requirements. 
 
Keywords 
 
Immediately after the abstract, provide a maximum of six keywords, avoiding general and plural terms and multiple 
concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the 
field may be used. 
 
Abbreviations 
 
Abbreviations in the text are discouraged. If a term appears repeatedly, however, an abbreviation may be introduced 
parenthetically at the initial mention of the term and used thereafter in place of the term. Abbreviations of 
conventional or SI units of measurement may be used without introduction. 
 
References to drugs 
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The generic name of a drug should be used as a general rule; however, the full name or the commercial name of the 
drug, as well as the name and location of the supplier, may be given in addition if appropriate. 
 
Bacterial nomenclature 
 
Microbes should be referred to by their scientific names according to the binomial system used in the latest edition of 
Bergey's Manual of Systematic Bacteriology (The Williams and Wilkins Co.). When first mentioned, the name should 
be in full and written in italics. Thereafter, the genus should be abbreviated to its initial letter, e.g. 'S. aureus' not 
'Staph. Aureus'. If abbreviation is likely to cause confusion or render the intended meaning(s) unclear the names of 
organisms should be given in full. Only those names included in the Approved Lists of Bacterial Names (Int J Syst 
Bacteriol 1980; 30: 225-420) and/or which have been validly published in the Int J Syst Bacteriol since January 1980 
are acceptable. If there is a good reason to use a name that does not have standing in nomenclature, it should be 
enclosed in quotation marks and an appropriate statement concerning its use made in the text (e.g. Int J Syst 
Bacteriol 1980; 30: 547-556). 
 
Symbols for units of measurement must accord with the Système International (SI) 
 
However, blood pressure should be expressed in mmHg and haemoglobin as g/dl. 
 
GenBank/DNA sequence linking 
 
Many Elsevier journals cite "gene accession numbers" in their running text and footnotes. Gene accession numbers 
refer to genes or DNA sequences about which further information can be found in the databases at the National 
Center for Biotechnical Information (NCBI) at the National Library of Medicine. Elsevier authors wishing to enable 
other scientists to use the accession numbers cited in their papers via links to these sources, should type this 
information in the following manner: 
 
For each and every accession number cited in an article, authors should type the accession number in bold, 
underlined text. Letters in the accession number should always be capitalised. (See example below). This 
combination of letters and format will enable Elsevier's typesetters to recognise the relevant texts as accession 
numbers and add the required link to GenBank's sequences. 
 
Example: "GenBank accession nos. AI631510, AI631511, AI632198, and BF223228), a B-cell tumor from a chronic 
lymphatic leukemia (GenBank accession no. BE675048), and a T-cell lymphoma (GenBank accession 
no. AA361117)". 
 
Authors are encouraged to check accession numbers used very carefully. An error in a letter or number can result 
in a dead link. In the final version of the printed article, the accession number text will not appear bold or 
underlined. In the final version of the electronic copy, the accession number text will be linked to the appropriate 
source in the NCBI databases enabling readers to go directly to that source from the article. 
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